GLP1R and type 2 diabetes mellitus: In the following, we describe the detailed procedures and illustrate them with a comparative safety study of glucagon-like peptide-1 receptor agonist (GLP-1ra; study drug) versus sulfonylurea (SU; comparator drug) for cardiovascular diseases (CVDs) in a population-based cohort with type 2 diabetes (T2D).